To include your compound in the COVID-19 Resource Center, submit it here.

Allos, AMAG Therapeutics Inc. deal

Hematology company AMAG and cancer company Allos will merge in a stock deal that values Allos at about $2.44 per share, or $258 million. The companies said the merger will allow a single

Read the full 336 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE